Back to search results

Study of Atezolizumab, Bevacizumab, and Memantine for Liver Cancer

This study is looking at a new combination of medicines for people with hepatocellular carcinoma (HCC), a type of liver cancer. It combines two standard treatments, Atezolizumab and Bevacizumab, with an additional drug called Memantine. Atezolizumab helps your immune system fight cancer, and Bevacizumab works by cutting off the blood supply to tumors. Memantine is being added to see if it can improve the effects of the other two drugs. The main goal is to see how many patients respond to this combination treatment. You might be able to join if you are 18 or older, have newly diagnosed HCC that hasn't been treated before, and have at least one measurable tumor. The study aims to enroll 19 participants, but its current status is unclear.

Study design
This study is testing a combination of three drugs in patients with liver cancer. It is an interventional study, but the phase is not specified.
What's involved
You would receive treatment in 21-day cycles over six months and complete quality of life surveys at each cycle.
Compensation
Not stated in the trial record.
Follow-up
The main outcome will be measured for up to 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06789757

The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)

Recruiting
PHASE2Ages 18+InterventionalTreatment
Inova Health Care Services
~19 participants
Updated 2025-10-07 on ClinicalTrials.gov
What's tested:Memantine HydrochlorideBevacizumabAtezolizumab

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Objective response rate (ORR) of patients who are treated with the combination of atezolizumab, bevacizumab, and memantine.
Measured over Up to 2 years

Conditions

Hepatocellular Carcinoma

Explore related trials

Hepatocellular Carcinoma

NCT06789757

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Inova Health Care Service

    Falls Church, Virginiastudy coordinator listed

    Recruiting

  • Inova Schar Cancer Institute - Fair Oaks

    Fairfax, Virginiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Arthur Winer, MD · PRINCIPAL_INVESTIGATOR · Principal Investigator

Who to contact

Keary Jane't
[email protected]
571-472-4724
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Absolute Neutrophil Count ≥ 1,500/μL
Platelets ≥ 100,000/μL
Hemoglobin ≥ 90 g/L (9g/dL)
Total Bilirubin ≤ 3 x ULN
AST(SGOT)/ALT(SGPT)/Alkaline Phosphatase ≤ 3 x ULN Or ≤5x ULN if due to liver involvement by tumor
Creatinine ≤ 2.0 mg/dL
eGFR (using Cockcroft Gault equation) \> 40ml/min 7. Chemotherapy is harmful to the human fetus. For this reason, sexually active males and females with partners of childbearing potential must agree to use an accepted and effective method of contraception prior to study entry and for the duration of the study. 8. Patients must demonstrate the ability to understand and the willingness to sign a written informed consent document. 9. Men and women, regardless of race, ethnic group, or sexual orientation are eligible for this study. 10. Patient must be able to swallow oral medication.

What this trial measures

  • Objective response rate (ORR) of patients who are treated with the combination of atezolizumab, bevacizumab, and memantine.Up to 2 years

    The effectiveness of the combination therapy using Azozolizumab, Bevacizumab,and Memantine in relation to the Objective Response Rate (ORR), defined as the proportion of complete or partial responses to the treatment by the response evaluation criteria for solid tumors(RECIST) 1.1.